Vericel Q3 revenue beats estimates on higher MACI product sales
Overview
US advanced therapies provider's Q3 revenue grew 26% yr/yr, beating analyst expectations
Q3 net income rose 179% to $14.2 mln; adjusted EBITDA margin reached 30%
Company raised full-year revenue and adjusted EBITDA margin guidance
Outlook
Vericel raises 2026 revenue guidance to $344-$346 mln from $330-$340 mln previously
Company raises 2026 MACI revenue guidance to $290-$292 mln from $284-$290 mln
Vericel raises 2026 Burn Care revenue guidance to $54 mln from $46-$50 mln
Result Drivers
MACI SALES - Co said MACI product sales drove revenue growth, with sixth consecutive qtr of 20%+ growth
BURN CARE SALES - Co said Burn Care segment, including Epicel and NexoBrid, saw record quarterly revenue and strong growth
SALES FORCE EXPANSION - Co attributed higher operating expenses to MACI sales force expansion and increased marketing
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $85.37 mln | $77.95 mln (8 Analysts) |
Q3 EPS | $0.27 | ||
Q3 Net Income | $14.16 mln | ||
Q3 Adjusted EBITDA | $25.20 mln | ||
Q3 Gross Margin | 73.00% | ||
Q3 Gross Profit | $62.61 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Vericel Corporation is $59.00, about 29.7% above its November 4 closing price of $45.48
The stock recently traded at 56 times the next 12-month earnings vs. a P/E of 62 three months ago
Reuters Recommended Reads
Nov 5 - Iovance Biotherapeutics Q3 revenue rises 80% on Amtagvi demand
Nov 3 - Tarsus Pharmaceuticals Q3 product sales jump 64%, beating estimates
Nov 3 - Sweden's Eco Wave Power Q3 net loss narrows 47%, operating expenses down 25%
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)